ArticleBiologicals : journal of the International Association of Biological Standardization2020
SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues.
Article in Biologicals : journal of the International Association of Biological Standardization, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.Biologicals : journal of the International Association of Biological Standardization · 2024Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.Nature medicine · 2022Article
- Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.Frontiers in microbiology · 2022Review
- Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study.Wellcome open research · 2022Article
- Vaccines against leishmaniasis: using controlled human infection models to accelerate development.Expert review of vaccines · 2021Article
- What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.The Lancet. Infectious diseases · 2021Review
- Human Challenge Studies With Wild-Type Severe Acute Respiratory Sydrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research.Open forum infectious diseases · 2021Article
- Vaccines for COVID-19.Clinical and experimental immunology · 2020Review
- Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.